<DOC>
	<DOCNO>NCT02723331</DOCNO>
	<brief_summary>The objective study estimate R0 resection rate patient Resectable Pancreatic Ductal Adenocarcinoma ( R-PDAC ) well Resectable Pancreatic Ductal Adenocarcinoma ( BR-PDAC ) independently response neoadjuvant sequential therapy combination nab-paclitaxel gemcitabine follow stereotactic body radiotherapy ( SBRT ) .</brief_summary>
	<brief_title>Perioperative Therapy Resectable Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates</brief_title>
	<detailed_description>Patients cohort receive total 3 cycle neoadjuvant combination chemotherapy nab-paclitaxel gemcitabine , follow re-staging CT scan , re-staging CT show evidence metastatic disease . Patients receive SBRT definitive surgical resection . Subsequently , patient receive 3 cycle adjuvant combination chemotherapy nab-paclitaxel gemcitabine . Each cycle combination chemotherapy total 4 week . Patients evaluated response completion 3 cycle neoadjuvant combination chemotherapy CT scan chest , abdomen pelvis . Patients undergo surveillance CT scan 3-month interval evidence disease progression .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically confirm resectable borderline resectable pancreatic adenocarcinoma . 2 . No evidence distant metastasis represent stage IV metastatic disease . 3 . RPDAC : No evidence distant metastasis tumor mass show extension superior mesenteric artery ( SMA ) hepatic artery . There must clearly define fat plane SMA celiac axis . Patent superior mesenteric vein ( SMV/portal vein ( PV ) distortion venous architecture . 4 . BRPDAC : define localize PDAC 1 follow feature : ) interface primary tumor superior mesenteric vein ( SMV ) portal vein ( PV ) measure 180o great circumference vein wall , and/or b ) shortsegment occlusion SMVPV normal vein level obstruction amenable resection venous reconstruction and/or c ) shortsegment interface degree tumor hepatic artery normal artery proximal distal interface amenable resection arterial reconstruction and/or ) interface tumor SMA celiac trunk measure less 180o circumference artery wall . 5 . Age &gt; 18 year old 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 7 . Patients must adequate bone marrow function : Platelets &gt; 100,000 cells/mm3 Hemoglobin &gt; 9.0 g/dL Absolute Neutrophil Count &gt; 1,500 cells/mm3 8 . Patients must adequate liver function : aspartate aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) &lt; 2.5 X upper limit normal Alkaline phosphatase &lt; 2.5 X upper limit normal , unless bone metastasis present absence liver metastasis Total bilirubin &lt; 1.5 mg/dL 9 . Patients must adequate renal function : creatinine &lt; 1.5 mg/dL recommend ; however , institutional norm acceptable . Creatinine within institutional limit normal creatinine clearance ( CrCl ) &gt; 50 mL/min calculate use CockcroftGault equation . 10 . Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment . 11 . Negative serum urine Î²human chorionic gonadotropin ( hCG ) pregnancy test screening patient childbearing potential . 12 . Patients must &lt; Grade 2 preexist peripheral neuropathy ( per CTCAE 4.03 ) . 13 . Ability understand willingness sign write informed consent . 1 . Patients locally advance surgically unresectable PDAC . 2 . Patients evidence distant metastatic PDAC . 3 . Prior chemotherapy radiation therapy kind treatment pancreas adenocarcinoma . 4 . Prior major surgery within 4 week start study drug administration . 5 . Patient unable willing perform study related biopsy blood draw exploratory endpoint enrol study study relate procedure mandatory . 6 . Concomitant treatment full dose warfarin ( coumadin ) NOT allow . However , treatment low molecular weight heparin ( LMWH ) ( enoxaparin dalteparin ) rivaroxaban allow . Patients full dose warfarin ( coumadin ) must transition either LMWH rivaroxaban prior administration study relate drug . 7 . Recent ongoing clinically significant gastrointestinal disorder ( e.g. , malabsorption , bleeding , inflammation , emesis , diarrhea &gt; grade 1 ) . 8 . Patients clinically significant cardiac disease ( New York Heart Association Classification III IV cardiac arrhythmia well controlled medication ) , myocardial infarction within previous six month . 9 . Serious , uncontrolled , concurrent infection ( ) require antibiotic . 10 . Pregnant breastfeed woman : positive pregnancy test within 7 day start treatment . 11 . Treatment carcinoma within last five year , except cure nonmelanoma skin treat insitu cervical cancer . 12 . Participation investigational drug study within 4 week precede start study treatment . 13 . Patients external biliary drain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>101 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Stereotactic Body Radiation Therapy</keyword>
	<keyword>Perioperative Therapy</keyword>
	<keyword>Resectable Pancreas Ductal Adenocarcinoma</keyword>
	<keyword>Borderline Resectable Pancreas Ductal Adenocarcinoma</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Neoadjuvant Therapy</keyword>
	<keyword>Adjuvant Therapy</keyword>
</DOC>